The HIV-1 capsid—essential for transporting the viral genome—must traverse the nuclear envelope through NPCs to deliver the viral DNA into the host nucleus, an indispensable step for viral integration and productive infection. The new study reveals that resting T cells inherently resist HIV-1 infection primarily because capsid nuclear import is inefficient. The nuclear envelope, a vital barrier punctuated by NPCs, tightly controls macromolecular trafficking between cytoplasm and nucleus. This barrier prevents the viral capsid from efficiently entering the nucleus, thus safeguarding resting T cells against infection.

Remarkably, HIV-1 overcomes this barrier through a mechanism involving cell-to-cell spread (CCS). Unlike cell-free viruses, direct contact between infected and uninfected T cells triggers CD4 receptor-mediated signalling cascades, notably involving the tyrosine kinase LCK and subsequent activation of cyclin-dependent kinase 1 (CDK1). This intracellular signalling remodels the architecture and function of nuclear pore complexes, enhancing their permeability or affinity for the viral capsid. These changes permit more rapid and efficient capsid nuclear import, thus licensing successful infection even in resting cells previously considered refractory.

Activated T cells are highly permissive to HIV-1 infection, consistent with decades of research showing that T cell activation enhances intracellular viral processes. Yet in vivo, the majority of T cells remain in a resting state. It has been contentious how infected resting T cells arise, with assumptions focusing on their prior activation and subsequent return to resting quiescence. The present findings suggest that direct CD4–LCK signalling at the virological synapse during CCS plays a pivotal role. By activating CDK1, this signalling remodels NPC components at a post-translational level, effectively transforming the nuclear entry gateway and broadening HIV-1’s infectious potential.

Central to this process is the remodeling of NPCs, intricate macromolecular structures constructed from over 30 nucleoporins forming a selective channel of approximately 120 megadaltons. Previous views emphasized select nucleoporins that directly interact with HIV-1 capsid as co-factors for infection. However, the study proposes a paradigm shift in which the entire NPC complex acts as a viral co-factor, dynamically adapting in response to HIV-1-induced signals. Remodeling events not only facilitate viral nuclear import but may also reshape host cell nuclear transport, influencing gene expression patterns.

The kinase CDK1, historically recognized for orchestrating mitotic entry, emerges as a crucial effector driving NPC phosphorylation and architectural remodeling. The study details widespread CDK1-dependent phosphorylation changes across cytoplasmic, central channel, and nuclear basket nucleoporins, including key components Nup54, Nup62, and TPR. These modifications alter the positioning and interaction potential of nucleoporins, potentially increasing NPC permeability or altering receptor-mediated transport to favor capsid translocation. This mechanistic insight fills vital gaps in understanding how HIV-1 negotiates the NPC barrier.

The authors observe enriched puncta of nucleoporins Nup54, Nup62, and TPR in association with incoming viral capsids, hinting at either the reorganization of existing nuclear pores or the assembly of nascent NPCs to facilitate capsid passage. While the exact ultrastructural ramifications remain unresolved, these findings emphasize dynamic nuclear pore plasticity in immune cells and raise questions about how environmental stimuli or immune activation cues sculpt NPC architecture.

Intriguingly, the study extends beyond virology to touch upon broader immunological implications. Co-stimulatory receptor CD4, classically appraised as an amplifier of antigen-specific T cell receptor (TCR) signalling, may directly activate LCK independently, thereby modulating CDK1 activity and nuclear transport even in the absence of canonical TCR engagement. This suggests that CD4 signalling imparts discrete regulatory capacities influencing T cell functional states, broadening the conceptual framework of peripheral T cell responses.

Given CD4’s expression on other immune populations lacking TCR—for example, macrophages and dendritic cells—this signalling axis might represent a more general mechanism tuning immune cell nuclear dynamics and function. Understanding this may inform new avenues for immunotherapy, harnessing co-stimulatory signalling pathways to fine-tune immune responses and develop tailored interventions.

Additionally, the enhanced nuclear import machinery may impact HIV-1 integration site selection and viral persistence. Nucleoporins influence chromatin organization proximal to nuclear pores, and signalling-induced NPC rearrangement may govern where HIV-1 inserts into the host genome. As integration sites affect viral transcriptional activity and immune recognition, this could have profound consequences for HIV-1 latency and pathogenesis.

The study’s focus on the juxtaposition of fine molecular signalling, nuclear pore remodeling, and viral nuclear import extends its significance. It highlights how localized extracellular interactions at the virological synapse cascade inward to modify host cellular architecture at the nuclear envelope, dramatically shifting the intracellular landscape to promote viral replication.

This paradigm also elucidates why cell–cell spread is significantly more efficient than cell-free infection. By promoting simultaneous viral transfer and host cell signalling that overcomes intrinsic nuclear entry restrictions, HIV-1 ensures robust infection of resting T cells in vivo. These discoveries thus redefine the interplay between viral transmission modes, host cell signalling pathways, and nuclear transport systems in HIV-1 pathogenesis.

Future research into other viruses that must traverse the NPC barrier—such as hepatitis B and herpesviruses—may uncover analogous strategies involving manipulation of nuclear pore dynamics and targeted signalling. This work serves as a foundational framework for exploring viral cooption of nuclear transport regulation, potentially revealing universal pathogen tactics.

Conclusively, the confluence of HIV-1 envelope engagement, CD4 receptor signalling, LCK activation, and CDK1-driven nuclear pore remodeling delineates a viral strategy finely tuned to circumvent cellular barriers in resting T cells. These insights advance our molecular understanding of viral-host interactions and open new therapeutic possibilities aiming to disrupt these essential viral processes, offering hope for improved management of HIV-1 infection and its immunological consequences.

Subject of Research: HIV-1 nuclear entry mechanisms and host cell nuclear pore complex remodeling

Article Title: HIV-1 signalling remodels nuclear pores to licence infection

Article References:
Mesner, D., Whelan, M.V.X., Shivkumar, M. et al. HIV-1 signalling remodels nuclear pores to licence infection. Nature (2026). https://doi.org/10.1038/s41586-026-10453-3

Image Credits: AI Generated

DOI: https://doi.org/10.1038/s41586-026-10453-3

In addition to the rapid mutation rate, the virus employs sophisticated immune evasion strategies that thwart the host’s adaptive immune response. HIV-1 is adept at hiding from the immune system, often altering its surface proteins to escape neutralization by antibodies produced during infection. This characteristic underscores the necessity for vaccines that can stimulate a robust, broad immune response capable of recognizing a wide range of viral variants.

Furthermore, HIV-1 establishes latent reservoirs within the host, particularly in immune cells like CD4+ T cells, which complicates eradication efforts. These reservoirs serve as hidden storage sites for the virus, allowing it to persist despite antiretroviral therapy that suppresses active viral replication. The permanence of these reservoirs poses a significant challenge to achieving long-term control over HIV-1 and adds urgency to the search for novel vaccine strategies that could potentially tackle this issue.

While antiretroviral therapies have transformed HIV-1 from a fatal disease to a manageable chronic condition, they come with their own set of limitations. Lifelong adherence to medication is required, which can be burdensome for individuals, leading to adherence challenges and potential treatment failure. Moreover, the emergence of drug-resistant strains due to incomplete treatment regimens further exacerbates the problem, highlighting an urgent need for alternative therapeutic and preventive measures.

One of the critical challenges in HIV-1 vaccine development is the induction of broadly neutralizing antibodies (bNAbs). These antibodies are essential for providing robust protection against diverse HIV-1 variants. However, the virus’s complex structure and the immunological tolerance of the host impede the effective generation of bNAbs through traditional vaccination approaches. Therefore, researchers have turned to innovative technologies like mRNA to address these challenges.

mRNA technology has gained prominence in recent years, particularly due to its rapid scalability and favorable safety profiles. Unlike traditional vaccine platforms, mRNA-based vaccines do not use live or attenuated virus, thereby avoiding risks associated with viral vector-based approaches. This eliminates concerns related to viral infections or adverse reactions tied to live vaccines, making mRNA an attractive option for HIV-1 immunization.

The use of mRNA allows for rapid iterations and customization in vaccine design. Researchers can swiftly modify the mRNA sequence to optimize the immunogen, thereby tailor-fitting it to target the specific viral antigens that are most likely to elicit a strong immune response. This flexibility could accelerate the development and testing of vaccine candidates aimed at eliciting bNAbs, potentially expediting the path toward a functional HIV-1 vaccine.

Preclinical studies are already underway, exploring various mRNA formulations and their effectiveness in stimulating an immune response against HIV-1. Animal models are being utilized to assess the immunogenicity of these vaccine candidates, with the goal of moving towards early-phase clinical trials. Initial findings appear promising, suggesting that mRNA-based vaccines can generate robust antibody responses and show potential in preventing HIV-1 infection.

Early-phase human clinical trials are beginning to provide insight into the safety and efficacy of mRNA technology in combating HIV-1. These studies aim to establish dose tolerability, immunogenicity, and the ability of the vaccine to induce bNAbs in human subjects. Although challenges remain, early results could pave the way for larger, more extensive trials that will ultimately determine whether mRNA vaccines have a viable role in HIV-1 prevention and treatment.

As the field advances, it is crucial for researchers to remain cognizant of the persistent challenges associated with HIV-1 vaccine development. Continued investigation into the mechanisms of viral evasion, the role of genetic diversity, and the establishment of latency will be vital for creating effective vaccines. Collaborative efforts among researchers, pharmaceutical companies, and public health organizations are essential to overcome these barriers and to usher in a new era of HIV-1 prevention.

Ultimately, the journey toward an effective HIV-1 vaccine will require innovative thinking, sustained funding, and rigorous scientific investigation. The potential benefits of effective immunization strategies cannot be overstated, not only in terms of public health impact but also in reducing the long-term healthcare burden associated with the ongoing management of HIV-1 infection. As mRNA technology holds unprecedented promise, it may represent a turning point in the fight against this enduring global health challenge.

In conclusion, while the road ahead is fraught with challenges, the advances in mRNA technology provide a glimmer of hope in addressing the limitations of current HIV-1 therapies and vaccines. The commitment to exploring this exciting frontier could ultimately lead to transformative outcomes for those affected by HIV-1, paving the way for a future where vaccination might prevent infection and curtail the ongoing epidemic.

Subject of Research: HIV-1 vaccine development using mRNA technology.

Article Title: mRNA technology for the prevention and treatment of HIV-1 infection.

Article References:

Liu, C., Yaremenko, A.V., Li, X. et al. mRNA technology for the prevention and treatment of HIV-1 infection.
Nat Rev Bioeng (2026). https://doi.org/10.1038/s44222-025-00387-2

Image Credits: AI Generated

DOI:

Keywords: mRNA technology, HIV-1, vaccine development, broadly neutralizing antibodies, immunization strategies.